Mankind Pharma has filed its Draft Red Herring Prospectus (DRHP) with the market regulator Securities and Exchange Board of India (SEBI).

The company’s initial public offering comprises an offer for the sale of 40,058,884 equity shares of face value Rs 1 each by selling shareholders including the promoters and existing investors.

The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

The offer for sale comprises up to 3,705,443 equity shares by Ramesh Juneja, up to 3,505,149 equity shares by Rajeev Juneja, up to 2,804,119 equity shares by Sheetal Arora, up to 17,405,559 equity shares by Cairnhill CIPEF, up to 2,623,863 equity shares by Cairnhill CGPE, up to 9,964,711 equity shares by Beige and up to 50,000 equity shares by Link Investment Trust.

The company is focused on the domestic market, as a result of which its revenue from operations in India contributed to 97.60 per cent of its total revenue from operations for the Financial Year 2022, which was one of the highest among peers identified by IQVIA.

Kotak Mahindra Capital Company, Axis Capital, IIFL Securities, Jefferies India and JP Morgan India are the Book Running Lead Managers for the issue.